Tag: Blepharitis treatment

Affecting an estimated 25 million people in the U.S., Demodex blepharitis is a common eyelid disease caused by an infestation of Demodex mites [1.8.6]. When patients ask, 'Can you repeat Xdemvy?', they are often wondering about long-term management of this chronic condition.

According to combined clinical trial data, approximately 50% of patients using Xdemvy for Demodex blepharitis achieved a significant reduction in collarettes by the end of the 6-week treatment period. Knowing how to monitor your progress is key to understanding if the medication is working effectively for you.

Affecting millions of people, *Demodex* blepharitis is a common eyelid condition caused by an overpopulation of tiny mites. While XDEMVY (lotilaner ophthalmic solution) is the only FDA-approved medication that specifically targets and kills these mites, several other treatment options exist for managing the condition and its symptoms. These alternatives range from other prescription medications to over-the-counter cleansers and in-office procedures.

Affecting nearly 25 million people in the U.S., Demodex blepharitis is a common inflammatory eyelid condition caused by an overgrowth of Demodex mites. For those wondering **how soon does Xdemvy start working**, some patients see improvement as early as two weeks.

Affecting millions of people, *Demodex* blepharitis is an inflammatory eyelid condition caused by microscopic mites. A standard treatment course is the typical way an ophthalmologist or optometrist determines **how often can Xdemvy be prescribed** to address this underlying cause.

An estimated 25 million eye care patients in the U.S. are affected by Demodex blepharitis. In response to this widespread condition, the FDA approved Xdemvy on July 24, 2023. So, to answer the question of **how long has Xdemvy been on the market?**, as of September 2025, it has been available for over two years.